It’s the second acquisition for BioMarin in 2025, as the company seeks to diversify its product portfolio after the ...

Venture capital firm Aditum Bio is going all-out for a new collaboration with Fosun Pharma, launching a subsidiary with the ...

Merck & Co. is turning down its option to license Evaxion’s gonorrhea vaccine candidate, closing the door on the Danish ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

The new saw: Development-stage biotechs are maturing. Their drugs are winning approvals and independent commercial launches ...

US drug makers are racing to plug looming 'patent cliff' revenue gaps - and increasingly they are turning to China biotechs ...

It took 27 years, but Cytokinetics secured its first U.S. drug approval. On Friday, the Food and Drug Administration cleared ...

Philadelphia has lagged in biotech R&D jobs despite University of Pennsylvania scientists playing a leading role in ...

RA Capital Management’s Peter Kolchinsky says the companies that survived the industry’s 2021 rout are thriving—and looking to make deals.

Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro ...

First, the Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU) seeks daily investment results, before fees and expenses, of 300% of the performance of the aforementioned biotech index. Second, the ...

The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...